Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors

Haematologica

Volumn 90, Issue 9, 2005, Pages 1288-1290

  Orsini, Frédérique ^a   Rotschild, Chantal ^b   Beurrier, Philippe ^b   Faradji, Albert ^b   Goudemand, Jenny ^b   Polack, Benoît ^a,c  

^a Grenoble University Hospitals   (France)

^b CHU de Grenoble ^*

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Factor VIII inhibitor; Hemophilia A; Immune tolerance; Von Willebrand factor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTENNAPEDIA PROTEIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; FACTANE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; PRESCHOOL CHILD; TREATMENT OUTCOME;

EID: 25444521967     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, Shima M, Ovanesov MV, Khrenov AV, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004;15:109-24.
2. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003; 88:EREP02.
3. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001;7:375-80.
4. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002;88:221-9.
5. Burnouf T, Burnouf-Radosevich M, Huart JJ, Goudemand M. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 1991; 60:8-15.
6. White GC, II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in hemophilia - recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
7. Rothschild C, Laurian Y, Satre EP, Derlon AB, Chambost H, Moreau P, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998;80:779-83.
8. Hausl C, Ahmad RU, Sasgary M, Doering C, Lollar PS, Richter G, et al. Inhibition of factor VIII-specific memory B cell responses by supra-physiological concentrations of factor VIII. Blood 2004;104:A38.
9. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation? Trends Cardiovasc Med 2001;11:251-7.
10. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003;88:EREP04.